|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, the prognosis of CRC patients was positively associated with the frequency of TDLN CD8<sup>+</sup>CXCR5<sup>+</sup> T cells, and with the expression of IFNG, PRF1, and GZMB expression by tumor and TDLN CD8<sup>+</sup>CXCR5<sup>+</sup> T cells.
|
29544815 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, tumor tissue excised from GrB/4D5/26-treated mice showed excellent delivery of GrB to tumors and a dramatic induction of apoptosis compared with saline treatment.
|
23493312 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In immunocompetent mouse 4T1 breast tumor model, intratumoral delivery of rAd.sT inhibited both tumor growth and lung metastases. rAd.sT downregulated the expression of several transforming growth factor β (TGFβ) target genes involved in tumor growth and metastases, inhibited Th2 cytokine expression, and induced Th1 cytokines and chemokines, and granzyme B and perforin expression. rAd.sT treatment also increased the percentage of CD8<sup>+</sup> T lymphocytes, promoted the generation of CD4<sup>+</sup> T memory cells, reduced regulatory T lymphocytes (Tregs), and reduced bone marrow-derived suppressor cells.
|
31126191 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In light of this, we evaluated the impact of induced regulatory T (iTreg) cells on the efficacy of tumour cell killing redirected by ImmTAC and demonstrated down-regulation of T-cell proliferation and expression of CD25, CD107a, Granzyme B and Perforin by ImmTAC-redirected T cells.
|
29791021 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In NK cells and CTLs the levels of active cathepsin C and of granzyme B are dependent on the concentration of monomeric, active cystatin F. In tumour microenvironment, inactive dimeric cystatin F can be secreted from tumour cells or immune cells and further taken up by the cytotoxic cells.
|
29748898 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In p50<sup>-/-</sup> mice, total tumor CD4 T cells are threefold more abundant, whereas CD8 T-cell numbers are unchanged, and both produce increased IFNγ and Granzyme B. Naïve splenic p50<sup>-/-</sup> CD8 T cells manifest increased activation, whereas naïve p50<sup>-/-</sup> and WT CD4 T cells show similar Th1, Th2, and Th17 polarization.
|
30030559 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo antilymphoma activity of HSP105 engagement was associated with a significant local increase of Granzyme B(+) killer cells that very likely contributed to the tumor-restricted necrosis.
|
21860023 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Including CTL and GZMB scores simultaneously in the model significantly improved the predictive performance of the models for all-cause and colorectal cancer-related death.<b>Conclusions:</b> Higher tumor infiltration with CTL and GZMB cells is associated with improved all-cause and cancer-specific survival of colorectal cancer patients.<b>Impact:</b> Both the number of CTLs and GZMB appear to be useful prognostic factors in colorectal cancer, irrespective of stage.
|
27979806 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Inhibition of autophagy by targeting beclin1 (BECN1) restored granzyme B levels in hypoxic cells in vitro and induced tumor regression in vivo by facilitating NK-mediated tumor cell killing.
|
24101526 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
More importantly, NK-92-S3KD immunotherapy increases the production of not only IFNγ, but also granzyme B and perforin in tumors; therefore, inhibiting cancer progression in two xenograft mouse models with human hepatoma (HepG2) and melanoma (A375).
|
29915022 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, in some tumor systems the immunosurveillance failure against cancer cells has been related to the presence of the granzyme B inhibitor PI-9.
|
27121069 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, our studies demonstrated that the anticancer activity of perforin and granzyme B was sustainable in vivo as tumor development by inducing cell apoptosis.
|
24696715 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
On day 12 and day 29, the immune-activation in the peripheral blood, tumors, and spleens were analyzed. rAd.DCN.GM increased CD8<sup>+</sup> T lymphocytes in the blood, upregulated perforin and granzyme B in the tumors, inhibited transforming growth factor beta expression, and promoted dendritic-cell production in the spleen.
|
28530155 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One further characterized cytotoxic CD8(+) T cell clone, that released TNF-alpha, IFN-gamma, and granzyme B upon co-incubation with the autologous tumor cells, was shown to be restricted by the remaining HLA-A11 allele, which was also shown to be expressed in the tumor tissue.
|
16924494 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our findings suggest that the increased of expression of GB in the tumor microenvironment of OCSCC and in lymph nodes may have beneficial effect against neoplastic cells, contributing to apoptosis of these cells and increased survival of patients.
|
20060355 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results have demonstrated that TILs have three different gene expression profiles: the first set of genes is involved in cell proliferation and mitogenic stimulation, such as c-myc and IL-8, LD78, MIP-1beta, insulin-induced protein and AH-receptor; the second set of genes includes those involved in attachment of lymphocytes to endothelium and extravasation into tumor tissues such as P-selectin ligand and integrin; and the third set, which includes genes such as the perforin, FAS ligand and granzyme B, is related to cytotoxic function to tumor cells.
|
11024287 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results show that targeted delivery of GrB to tumor vascular endothelial cells or to tumor cells activates apoptotic cascades and this completely human construct may have significant therapeutic potential.
|
23858102 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Paired t test showed an increase of GRANZYME-B+ lymphocytes density in LN metastasis compared to the corresponding primary tumor, suggesting that LN metastasis is enriched with activated immune cells.
|
28730569 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
QIF is used to simultaneously measure the level of CD3+ tumor infiltrating lymphocytes (TILs), in situ T-cell proliferation (Ki-67 in CD3) and effector capacity (Granzyme-B in CD3).
|
30097571 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Quantitative PCR analysis showed an increased expression of granzyme B and perforin mRNA levels in LT12 when cocultured in the presence of the primary tumor.
|
16773195 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Reductions in GzmB in intratumoral CD8+ T cells in combination with the changes in tumor microenvironment that maintain the ability of CSCs to self-renew and even confer this capability to the nonstem population are compatible with reduced immunosurveillance and adverse tumor outcomes in animal models of OSA.
|
28364502 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Saline-treated tumors increased 24-fold, whereas tumors treated with GrB/scFvMEL showed a significant tumor growth delay increasing four-fold.
|
16611405 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Similarly, there was robust granzyme B staining localizing to the tumors; affirming the presence of cytotoxic immune cells within the tumor.
|
29930558 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Since the immune status of the tumor microenvironment could play a role in the history of disease, we evaluated the expression of CD45, CD14, ARG1, CD163, CD4, FOXP3, Perforin-1 (PRF1), Granzyme B (GRMB), and IL-10 mRNAs in primary tumors at diagnosis from children with metastatic NB and tested whether the transcript levels are significantly associated to event-free and overall survival (EFS and OS, resp.).
|
26161395 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
T cell cytotoxicity was mediated via granzyme B release and mediated enhanced tumor control <i>in vivo</i>.
|
30214445 |
2018 |